BioMarin Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Alexander Hardy
Chief executive officer
US$18.6m
Total compensation
| CEO salary percentage | 0.3% |
| CEO tenure | less than a year |
| CEO ownership | 0.01% |
| Management average tenure | 3.2yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$322m |
| Jun 30 2024 | n/a | n/a | US$257m |
| Mar 31 2024 | n/a | n/a | US$205m |
| Dec 31 2023 | US$19m | US$65k | US$168m |
Compensation vs Market: Alexander's total compensation ($USD18.59M) is above average for companies of similar size in the BR market ($USD5.75M).
Compensation vs Earnings: Insufficient data to compare Alexander's compensation with company performance.
CEO
Alexander Hardy (55 yo)
less than a year
Tenure
US$18,586,001
Compensation
Mr. Alexander Hardy serves as President, Chief Executive Officer & Director of BioMarin Pharmaceutical Inc. since December 01, 2023. He had been Chief Executive Officer at Genentech, Inc. since March 1, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$18.59m | 0.0099% R$ 7.7m | |
| CFO & Executive VP | 4.9yrs | US$4.85m | 0.038% R$ 29.4m | |
| Executive VP & CTO | no data | US$5.70m | 0.012% R$ 9.4m | |
| Advisor | 8.2yrs | US$9.66m | 0.097% R$ 76.0m | |
| Group VP & Chief Accounting Officer | 2.6yrs | no data | 0.00071% R$ 555.5k | |
| Chief Scientific Officer & Senior VP of Research and Early Development | no data | no data | no data | |
| Group Vice President of Investor Relations | no data | no data | no data | |
| Executive VP | 20.9yrs | US$5.19m | 0.029% R$ 23.1m | |
| Senior VP & Chief Marketing Officer | 2.6yrs | no data | no data | |
| Executive VP & Chief People Officer | 5.9yrs | no data | no data | |
| Senior Vice President of Technical Development | 3.2yrs | no data | no data | |
| Executive VP & Chief Corporate Affairs Officer | less than a year | no data | no data |
3.2yrs
Average Tenure
54yo
Average Age
Experienced Management: B1MR34's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$18.59m | 0.0099% R$ 7.7m | |
| Independent Chairman of the Board | 18yrs | US$515.44k | 0.060% R$ 46.7m | |
| Independent Director | 8.9yrs | US$470.44k | 0.021% R$ 16.8m | |
| Independent Director | less than a year | US$213.38k | no data | |
| Independent Director | 22.4yrs | US$486.44k | 0.049% R$ 38.2m | |
| Independent Director | 8.4yrs | US$480.44k | 0.012% R$ 9.6m | |
| Independent Director | 3.8yrs | US$473.94k | 0.0065% R$ 5.1m | |
| Independent Director | 7.3yrs | US$486.94k | 0.014% R$ 10.8m | |
| Independent Director | less than a year | US$213.38k | no data | |
| Independent Director | 5.4yrs | US$480.44k | 0.0099% R$ 7.8m | |
| Independent Director | less than a year | US$213.38k | no data |
5.4yrs
Average Tenure
64yo
Average Age
Experienced Board: B1MR34's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 19:36 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioMarin Pharmaceutical Inc. is covered by 56 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Ishan Majumdar | Baptista Research |
| Huidong Wang | Barclays |